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Abstract: Treatment of castration-resistant prostate cancer (CRPC) remains challenging due to
the development of drug resistance. The Warburg effect describes the ability of cancer cells to
consume larger amounts of glucose compared to normal tissues. We identified derivatives of natural
1,4-naphthoquinones to be active in CRPC and further synthetically modified them via glucose
conjugation to increase selectivity by Warburg effect targeting. Mechanisms of action were examined by
quantitative proteomics followed by bioinformatical analysis and target validation. Four synthesized
molecules revealed the highest selectivity towards human CRPC cells, which correlated with higher
GLUT-1 activity and expression. The compounds were able to induce pro-apoptotic signs and to inhibit
the pro-survival processes and mechanisms of drug resistance (i.e., AR-signaling and autophagy).
Proteome analysis suggested a disruption of the mitochondria/oxidative phosphorylation, which
was validated by further functional analysis: thus, mitochondria depolarization, elevated levels of
cytotoxic ROS, an increase of Bax/Bcl-2 ratio as well as release of mitochondrial AIF and cytochrome
C to cytoplasm were observed. In conclusion, glucose-conjugated 1,4-naphthoquinones show potent
activity and selectivity in human CRPC exerted via mitochondrial targeting. The compounds can
overcome drug resistance against current standard therapies and suppress pro-survival mechanisms.
This unique combination of properties makes them new promising candidates for the treatment
of CRPC.
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1. Introduction
Despite continuous progress in the treatment of metastatic castration-resistant prostate cancer
resistance development remains a major challenge during the course of treatment with decreasing
response rates and reduced progression free and overall survival with each additional treatment
line [1]. Thus, cross resistance has been observed between androgen receptor targeting therapies with
a > 50% PSA decline of only 4% when abiraterone is applied after enzalutamide [2]. Conventional
chemotherapies can cause severe side effects due to a lack of sensitivity and specificity limiting the use
especially in patients with comorbid conditions, a poor performance status and/or high chronological
age [3]. Consequently, there is a high medical need for novel anticancer drugs characterized by
innovative mechanisms of action and increased selectivity in prostate cancer.
Tumor cells exhaust more energy for proliferation than normal cells by consuming excessive
amounts of glucose via overexpressed sugar binding and transporting receptors (mainly GLUTs) [4].
Interestingly, even in aerobic conditions the cancer cells prefer glycolysis followed by lactate
fermentation over more energetically efficient oxidative phosphorylation. This process which was
called “aerobic glycolysis” leads to the generation of extra amounts of metabolites, which may be
beneficial for the rapidly proliferating cancer cells [5]. This phenomenon known as the “Warburg
effect” attracts attention as one of the promising strategies for specific tumor targeting. Thus, binding
of small cytotoxic “warhead” molecules to sugar residues may increase selectivity due to the higher
uptake by cancerous cells [4,6]. Glufosfamide was the first sugar-conjugated compound which has
been synthesized [7], successfully passed several clinical trials [8] and is currently undergoing Phase
III trials in metastatic pancreatic cancer. Remarkably, the glycosylated derivatives of several cytotoxic
drugs, e.g., chlorambucil, busulfan, docetaxel and paclitaxel have been found to be less toxic to normal
cells than their parent aglycons [9]. Due to the chemical reactivity of the hydroxyl group at C1 of
glucose (glycoside hydroxyl) most of these derivatives were synthesized as glycosides (i.e., conjugated
at C1 position) [9]. For such prodrug compounds it has been shown that after entering the cells via
GLUT receptors (mainly GLUT-1) the glycoside bond is hydrolyzed. Thus, the glucose residue is
eliminated and consequently metabolized either via anaerobic or aerobic pathway (the latest involves
Krebs cycle which takes place in the mitochondria matrix). While the unconjugated active aglycon
(drug) further exerts its cytotoxic action inside the cancer cell [4].
Despite the progress in synthetic chemistry and computational biology up to 50% of the
drugs used nowadays in clinic (particular in oncology) have been created on the basis of natural
products [10]. These molecules are frequently characterized by unique physiological properties.
Synthetic modification and structure optimization may further increase selectivity and decrease toxic
side effects [10]. In the current study, we identified derivatives of several natural compounds with a
1,4-naphthoquinone structural moiety which showed promising cytotoxic activity in CRPC cell lines
harboring different resistance patterns. Remarkably, a quinone moiety is present in different standard
chemotherapies, e.g., dactinomycin, mitomycin-C and anthracyclines [11]. 1,4-Naphthoquinones,
being the most important and widely distributed chemical class in the quinones, exhibit anticancer as
well as antiallergic, antibacterial, antifungal, anti-inflammatory, antithrombotic, antiplatelet, antiviral,
lipoxygenase, radical scavenging and anti-ringworm activities [11]. Despite the pronounced anticancer
activity the mechanism of action is still poorly understood [11,12]. Inhibition of topoisomerase-II [13,14]
as well as formation of semiquinones and superoxide radicals resulting in dsDNA breaks [15] have
been reported for some of these compounds (reviewed in [11,12]). Recently, we showed that cell death
induced by 1,4-naphthoquinones may have a p53-independent character [16].
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Thus, in order to increase selectivity of the identified 1,4-naphthoquinones by Warburg
effect targeting we further generated glucose derivatives of these compounds. For this purpose
we used a new modified alkylation reaction of 2-hydroxy-1,4-naphthoquinones with 6-deoxy-6-
iodo-1,2:3,5-di-O-isopropylidene-α-D-glucofuranose. This reaction is a more efficient variant compared
to transesterification of methoxynaphthazarin derivatives, which has been recently reported by
us [16,17]. Thus, we were able to synthesize chimera molecules which possess a 1,4-naphthoquinone
“warhead” moiety and a glucose residue, conjugated to each other via unusual non-glycoside bond.
Three groups of the molecules were generated, namely diprotected [diisopropylidene derivatives
which have no unsubstituted (no free) hydroxyl groups in the glucose moiety, e.g., compound 2],
monoprotected [monoisopropylidene derivatives which have two unsubstituted hydroxyl groups in
the glucose moiety, e.g., compound 3) and unprotected conjugated [free-glucose derivatives, glucose
moiety has four unsubstituted hydroxyl group, e.g., compound 4]. Here, we report on the synthesis,
anticancer activity and mechanism of action as well as on Warburg effect guided selectivity in CRPC of
new quinone-carbohydrate conjugates in vitro.
2. Results
2.1. Activity of 2-Methoxy-1,4-Naphthoquinones in Human Drug-Resistant Prostate Cancer Cells
In continuation of the search for new natural compounds and their synthetic derivatives
capable of overcoming the resistance of drug-resistant prostate cancer, we identified several
2-methoxy-1,4-naphthoquinones to be active in human prostate cancer PC-3 cells, known to be
docetaxel-resistant and hormone-independent (due to the absence of AR expression) (compounds 1, 5,
9, 13, 17, 21, and 25; Tables S2 and S4). However, the cytotoxicity of these compounds was comparable
in malignant PC-3 cells and in human prostate non-cancer PNT2 cells (Table S4). Thus, we further
modified these molecules and synthesized a library of 21 compounds containing a conjugated quinone
and glucose moieties, linked via a non-glycoside bond (Figure 1A,B). These synthetic modifications have
been postulated to increase the selectivity towards human cancer cells due to Warburg effect targeting.
2.2. Synthesis of the 6-O-(1,4-Naphthoquinone-2-yl)-D-Glucose Conjugates
For the synthesis, the small bioactive natural compounds lawsone (1a), the derivatives of
juglone (5a, 9a) and naphthazarin (13a, 17a, 21a and 25a) were chosen as the starting “warhead”
molecules (Figure 1A, Table S1). A novel effective reaction of 2-hydroxy-1,4-naphthoquinones with
1,2:3,5-di-O-isopropylidene-6-deoxy-6-iodo-α-D-glucofuranose (1b) was applied to conjugate the
quinone and D-glucose moieties. Monoprotected (monoisopropylidene) glucose conjugates (3, 7,
11, 15, 19, 23, 27) were prepared by acetic acid hydrolysis of diprotected (diisopropylidene) glucose
conjugates (2, 6, 10, 14, 18, 22, 26). Conjugates, containing unprotected glucose (4, 8, 12, 16, 20,
24, 28), were synthesized by trifluoroacetic acid hydrolysis of monoprotected glucose conjugates.
For further biological studies, we used the methyl ethers of the corresponding quinone derivatives
as “reference” compounds–molecules containing active 1,4-naphthoquinone core and non-glucose
substituted (compounds 1, 5, 9, 13, 17, 21, 25).
2.3. Screening for Cytotoxicity and Selectivity to Human Prostate Cancer Cells
Next, we performed examinations of cytotoxicity and selectivity against human drug-resistant
prostate cancer cells. We further examined the newly synthesized diprotected (2, 6, 10, 14, 18, 22, and
26), monoprotected (3, 7, 11, 15, 19, 23, and 27) and unprotected glucose conjugates (4, 8, 12, 16, 20, 24,
and 28), the corresponding methyl ethers as reference compounds (1, 5, 9, 13, 17, 21, and 25) as well as
anisomycin (positive control). Therefore, the same biological model was used–namely prostate cancer
PC-3 cells and prostate non-cancer PNT2 cells.
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Figure 1. Cytotoxic activity of the synthesized compounds in cancer and non-cancer cells. (A,B) The 
scheme of the synthesis (A) and the structures (B) of the investigated conjugates. (C) Selectivity index 
values–the ratio of IC50 in PNT2 cells to IC50 in PC3 cells. “#”–IC50 values towards the tested cell lines 
were >100 µM. The IC50s values are correspondent to those presented in Table S4. (D,E) The 
cytotoxicity profile of the compounds 7, 8, 11, and 12 in prostate cancer and non-cancer cells. IC50s 
Figure 1. Cytotoxic activity of the synthesized compounds in cancer and non-cancer cells. (A,B) The
scheme of the synthesis (A) and the structures (B) of the investigated conjugates. (C) Selectivity index
values–the ratio of IC50 in PNT2 cells to IC50 in PC3 cells. “#”–IC50 values towards the tested cell lines
were >100 µM. The IC50s values are correspondent to those presented in Table S4. (D,E) The cytotoxicity
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profile of the compounds 7, 8, 11, and 12 in prostate cancer and non-cancer cells. IC50s were evaluated
after 48 h of treatment using MTT test. Each dot represents IC50 towards certain human cell line (E).
Anisomycin was used as a reference substance. Statistical significance: * p < 0.05 (Student’s t-test).
In general, the selectivity index (SI) for glucose-quinone conjugates containing unprotected sugar
residue (e.g., 8 and 12) was higher than for the related methoxylated compounds without a sugar
moiety (e.g., 5 and 9) as well as mono- (e.g., 7 and 11) or diprotected derivatives (e.g., 6 and 10)
(Figure 1C). However, their absolute cytotoxicity was significantly lower than of the other compounds
belonging to the same structural group and IC50s often exceeded 100 µM (for details see Supplementary
Information, Table S4). Nevertheless, we identified two derivatives, 8 and 12, with unprotected glucose
residues, which revealed SI ≥ 2 and IC50 < 100 µM. For further examinations we chose these substances
as well as compounds 7 and 11–monoprotected glucose conjugates residues belonging to the same
structural groups like 8 and 12. Compounds 7 and 11 showed high absolute cytotoxicity and rather
high SI values (Figure 1B,C, Table S4).
The four selected compounds 7, 8, 11, and 12 were then examined in a panel of human prostate
cancer cell lines with varying levels of drug resistance as well as in five human non-cancer cell
lines to gain further information on selectivity. Among others, PC-3 and DU145 (docetaxel-resistent,
androgen-independent), 22Rv1 and VCaP (docetaxel-sensitive, androgen-independent, androgen
receptor variant 7 (AR-V7) positive), and LNCaP (docetaxel-sensitive, androgen-dependent) prostate
cancer cell lines were examined [18,19]. All four compounds exhibited selective cytotoxicity to prostate
cancer cell lines. However, the activity and selectivity of 8-hydroxyquinone-2-yl (3-hydroxyjuglone)
derivatives 11 and 12 was higher than of 5-hydroxyquinone-2-yl (2-hydroxyjuglone) derivatives 7 and
8 (Figure 1D,E). Of note, anisomycin used as a positive control was more cytotoxic in non-cancer cells
and no selectivity was found (Figure 1D).
2.4. Cytotoxicity of the Synthesized Compounds Correlates with GLUT-1 Expression and Glucose Uptake Rate
in Cancer Cells
Next, we evaluated whether the anticancer activity and selectivity of the compounds correlate
with glucose transporter-1 (GLUT-1) expression, as initially postulated. As expected, the mean GLUT-1
protein expression was 2.3-fold higher in prostate cancer cell lines than in non-cancer lines measured
by ELISA (Figure 2A). The deletion of glucose from the culture media caused increased cytotoxicity
of the tested compounds in both PC-3 and 22Rv1 cells (Figure 2B). Moreover, glucose uptake in
human prostate cancer PC-3 and 22Rv1 cells was inhibited by the synthesized compounds (Figure 2C).
These results could be well explained by the competitive binding of glucose and the investigated
substances to GLUT-1. This is another strong evidence that the synthesized conjugates reveal affinity
to GLUT-1 and are capable of targeting this pathway.
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2.5. Effect on Prostate Cancer Cell Proliferation, Colony Formation and Viability
W have fur her examined the anticancer in vitro activity of the most promising compounds in
human drug-resistant 22Rv1 cells. 22Rv1 cells express both AR full length (AR-FL) as well as AR-V7,
whereas PC-3 cells are AR-FL- and AR-V7-negative [20]. Thus, 22Rv1 cells are suitable for monitoring
of the both AR-FL- and AR-V7-mediated signaling [20]. Therefore, for the further experiments 22Rv1
cells were chosen as a main model, which is probably more clinically-relevant in comparison with
PC-3 cells.
Thus, all four selected conjugates 7, 8, 11, and 12 were able to suppress cancer cell colony
formation of AR-V7-positive 22Rv1 cells from single cells treated with non-cytotoxic concentrations
for 48 h (Figure 3A). The anti-proliferative activity was determined by trypan blue exclusion assay
(Figure 3B). Interestingly, the IC50s determined with trypan blue exclusion assay for compounds 7 and
11 (monoprotected glucose conjugates) (Figure 3B) were higher in comparison with the values estimated
using MTT test, whereas for compounds 8 and 12 (unprotected glucose-quinone conjugates) the values
were comparable. It is known that MTT tests access the metabolic activity of the cells [21], whereas trypan
blue exclusion assays differentiate between the cells with intact or disrupted cellular membrane [22].
This suggests that monoprotected glucose conjugates 7 and 11 may primary suppress cancer cell
metabolism, while non-protected glucose conjugates 8 and 12 may have higher membranotropic
activity. Of note, no effect on the cell cycle progression was observed for 22Rv1 cells treated with any
of the four tested compounds (Figure 3C).
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analyzed and quantified using the Cell Quest Pro software. (F,G), The Western blotting analysis of 
the expression of pro- and anti-apoptotic proteins (F) as well as autophagy and AR-signaling related 
proteins (G) in 22Rv1 cells after 48 h of treatment. β-actin was used as a loading control. Cells treated 
with 10 µM of anisomycin (Aniso) for 48 h were used as a positive control. Statistical significance: * p 
Figure 3. Cytostatic and proapoptotic a f the selected conjugates. (A) Colony formation assay.
The 22Rv1 cells were treated it t e i dicated concentrations of the c mpounds for 48 h, seeded
in 6-well plates and incubated for 14 days. Cancer cell colonies were stained and counted by naked
eye. (B), Cell viability and IC50s estimated in 22Rv1 cells using the trypan blue exclusion assay
after 48 h of treatment. (C–E), Flow cytometry analysis of 22Rv1 cells treated with the investigated
compounds for 48 h. (C,D), PI single staining: analysis of cell cycle. Apoptotic cells were detected
as sub-G1 population (D). (E), Annexin-V-FITC/PI double staining. Cells appeared in low right
quadrant (Annexin-V-FITC+/PI-) were considered to undergo early apoptosis. Flow cytometry data
were analyzed and quantified using the Cell Quest Pro software. (F,G), The Western blotting analysis
of the expression of pro- and anti-apoptotic proteins (F) as well as autophagy and AR-signaling related
proteins (G) in 22Rv1 cells after 48 h of treatment. β-actin was used as a loading control. Cells treated
with 10 µM of anisomycin (Aniso) for 48 h were used as a positive control. Statistical significance: * p <
0.05 (ANOVA followed by a post-hoc Dunnett’s test). Detailed information of Figure 3F,G (Western
blotting) can be found at Figure S1.
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The apoptosis-inducing activity of the compounds was examined by flow cytometry. Thus,
a dose-dependent DNA fragmentation (Figure 3D) as well as phosphatidylserine externalization
(Figure 3E) was detected in treated prostate cancer cells, indicating an apoptosis induction. In line with
these results, the western blotting analysis of 22Rv1 cells treated with the different compounds for 48 h
revealed dose-dependent induction of PARP and caspase-3 cleavage (apoptotic markers, Figure 3F), as
well as down-regulation of the anti-apoptotic protein survivin (Figure 3F). Additionally, up-regulation
of pro-apoptotic p21 was observed under the treatment followed by its down-regulation/degradation
at higher cytotoxic concentrations (Figure 3F).
2.6. Effect on Resistance Mediating Autophagy and Androgen Receptor Splice Variant-7 Expression
Autophagy contributes to survival of cancer cells, e.g., by mediating resistance to standard
therapies [23,24]. Proteins LC3 (isoforms I and II) and SQSTM1 (or p62) are major players in this
process and therefore are commonly used markers for autophagy alteration [25]. Up-regulation of
LC3B-II may indicate either inhibition or activation of autophagy, while simultaneous accumulation of
LC3B-II and SQSTM1 generally indicates inhibition of autophagy [25]. In 22Rv1 cells accumulation of
both, LC3B-II and SQSTM1, was detected at pre-cytotoxic and cytotoxic concentrations of compounds
7, 8, 11, and 12 (Figure 3G) indicating an inhibition of autophagy.
Androgen receptor (AR) signaling mediates survival and progression of human prostate cancer [26].
The inhibition of this pathway by AR-targeting drugs, e.g., abiraterone and enzalutamide, leads to
suppression of cell growth and ultimately to cell death. Resistance to these drugs is mediated by
different mechanisms, such as AR-V7 expression [27]. AR-V7 lacks the C-terminal ligand binding
domain and is a constantly activated transcriptional factor promoting cancer cell growth [26,27].
Compounds 7, 8, 11, and 12 downregulated both, AR full length (AR-FL) and AR-V7 in 22Rv1 after 48
h treatment (Figure 3G). This effect may contribute to the drug-induced cell death and may lead to the
reduction of the cancer cells drug-resistance.
2.7. Analysis of Changes in Proteome of Cancer Cells under Treatment With Synthesized Compounds
A global proteome screening approach was applied to further analyze the mode of action
and molecular targets of the synthesized compounds. For this analysis the effect of the cytotoxic
concentrations of compound 11 (most active conjugate in previous experiments) on the proteome of
22Rv1 cells was examined using the LC-MS/MS technique in data independent acquisition (DIA) mode.
In total, 2163 proteins were quantified across all samples. 274 proteins had 1.5 ≤ fold change ≤ 1/1.5
and were significantly regulated (p ≤ 0.05) (see Supplementary Information, Table S5). We identified
92 proteins out of this pool with increased expressional levels (upregulation) and 182 with decreased
expressional levels (downregulation) following the treatment. To analyze the proteomics data we
used the Ingenuity Pathways Analysis tool (IPA, QIAGEN Bioinformatics, Redwood, CA, USA). Gene
ontology, functional analyses as well as pathway network analyses were performed (Figure 4A–D).
z-Score algorithm was used to predict the direction of alteration for the current activity or function:
positive values indicate activation, negative values indicate suppression (Figure 4B,C). Interestingly,
the majority of the proteins regulated under the treatment were enzymes localized in cytoplasm and
nucleus (Figure 4A). The activity of several important cancer-relevant upstream regulator molecules
was predicted to be affected (Figure 4B). Among them, up-stream tyrosine kinase receptor ErbB-2 [28],
Rab-like protein 6 (RABL6) [29], microphthalmia-associated transcription factor (MITF) [30], which are
involved in progression and development of several types of cancer were predicted to be suppressed
(Figure 4B). In addition, canonical EIF2 and NER pathway as well as oxidative phosphorylation were
predicted to be suppressed, while LXR/RXR, sirtuin, sumolaytion, ILK, RhoA, actic cytoskeleton
signaling and NRF2-mediated oxidative stress response were activated (Figure 4C). Note, the IPA
analysis predicted an activation of androgen receptor under the drug treatment (Figure 3G). However,
we previously demonstrated the down-regulation of AR-FL as well as AR-V7 (Figure 3G). AR may
be activated by phosphorylation, whereas the down-regulation/degradation of the total AR may
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eventually lead to the ultimate and general inhibition of AR signaling [31]. These events may appear
independently from each other and thus will be further analyzed.
Five top hypothetical protein interaction networks were constructed using IPA software (Figure 4D).
Treatment with compound 11 was predicted to affect kinases JNK1/2, p38, ERK1/2, MEK1/2, and Akt.
Consequently, these kinases were placed in central positions of the networks (Figure 4D, marked with
red target sign). To verify this hypothesis western blotting analyses were performed. As many stress
kinases are known to be often activated shortly after stimulation, we used a short-term treatment of 2 h
in order to validate the predicted alterations and elucidate their possible role as an early biochemical
event following the treatment. Indeed, in line with the IPA analysis a pronounced activation of two
main stress MAPKs–p38 and JNK1/2, as well as slight Akt activation were detected (Figure 4E), while
pro-survival ERK1/2 was suppressed (Figure 4E). No significant alteration of MEK1/2 (an upstream
kinase of ERK1/2) was observed (Figure 4E).
Interestingly, an oxidative phosphorylation (along with eIF2 signaling and NER pathway) was
predicted to be significantly suppressed under the treatment (z-score = −2.887, p-value = 1.02 ×
10−8; Figure 4F). Proteins which are important components of all five main complexes, Complex
I (NADH-coenzyme Q oxidoreductase, genes NDUFA4, NDUFV1, NDUFS1, NDUFA6, NDUFA12,
NDUFA3, NDUFA2), Complex II (succinate-Q oxidoreductase, gene SDHB), Complex III (Q-cytochrome
c oxidoreductase, gene UQCRFS1), Complex IV (cytochrome c oxidase, genes COX6B1, COX17), and
Complex V (ATP synthase, gene ATP5PB) were down-regulated by compound 11 (Figure 4F, Table S5).
Thus, proteomics data strongly suggested the disruption of oxidative phosphorylation in cancer cells.
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used as a loading control. Detailed information of Figure 4E (Western blotting) can be found at Figure
S2. (F) Representative schema of oxidative phosphorylation signaling built by IPA software. The
molecule discovered by proteomics to be affected in cells under 22Rv1 treatment are indicated by color.
2.8. Mitochondria Are a Primary Target of Quinone-Glucose Conjugates 7 and 11 in Prostate Cancer Cells
Oxidative phosphorylation, which was predicted by the global proteomic screening followed
by the bioinformatical analysis to be suppressed under the drug treatment, takes place in the inner
mitochondrial membrane [32]. Thus, we investigated the effect of compound 11, as well as of
struct rally-related compound 7, o itochondria of human prostate cancer cells. First, the effect
on S level, which is often associated wit the disruption of mitochondrial integrity (r viewed
in [33]), . Ind ed, a remarkable and significant increase of the ROS level was observed
already after 2 h of treatment in 2 Rv1 re 5A,B). Next, the impact of ROS alterati n for
cytotoxic activity of the investigated co o s as determined. Thus, cancer cells were treated
with the drugs following pre-treatment with well-established antioxidant N-acetyl-L-cysteine (NaC,
Figure 5C). Remarkably, pre-treatment with NaC significantly suppressed the cytotoxic activity of both
compounds 7 and 11 (Figure 5C).
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Figure 5. Quinone-glucose conjugates 7 and 11 primary target mitochondria of human prostate cancer
cells. (A,B) Effect on ROS production in 22Rv1 cells. Cells were pretreated with CM-H2DCFDA
followed by treatment with indicated concentrations of the investigated drugs for 2 h. Cells were
harvested, analyzed by flow cytometry technique (A) and quantified using the Cell Quest Pro software
(B). H2O2-treated cells were used as a positive control. (C) Effect of N-acetyl-L-cysteine (NaC) on the
cytotoxicity of compounds 7 and 11. 22Rv1 cells were pre-treated with 1 mM NaC for 1 h and then
co-treated with the investigated drugs for 48 h in FBS- and glucose-free RPMI media. Cell viability was
measured by MTT test. (D,E) The induction of mitochondrial membrane potential (MMP, ∆Ψm) loss
by the drugs. 22Rv1 cells were treated for either 2 h or 48 h in PBS, harvested, stained with JC-1 and
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analyzed by flow cytometry technique. Numbers indicate the percentage of cells showing a drop in red
fluorescence intensity, which corresponds to mitochondria depolarization. Cells showing ∆Ψm loss
have been quantified using Cell Quest Pro software (E). Cells treated with 50 µM CCCP for indicated
time were used as a positive control. (F) 22Rv1 cells were treated with indicated concentrations of
compounds 7 and 11 for 48 h. Proteins were isolated and fractionated using Cell Fractionation Kit
(abcam), and the fractions were analyzed by Western blotting. Cells treated with 50 µM CCCP were used
as a positive control. (G) Analysis of Bax and Bcl-2 expression in 22Rv1 cells following 48 h treatment.
(H) Analysis of caspase-3 and -9 activation in 22Rv1 cells following 2 h and 48 h treatment. (I) Suggested
mode of action of compounds 7 and 11 and other similar compounds. Statistical significance: * p <
0.05 (Student’s t-test, section C; or ANOVA followed by a post-hoc Dunnett’s test, sections B and E).
Detailed information of Figure 5F–H (Western blotting) can be found at Figures S3–S5.
As the protein complexes which are involved in oxidative phosphorylation and potentially affected
by the drugs are localized in the inner mitochondrial membrane (Figure 4F), we further checked the
effects of conjugates 7 and 11 on ∆Ψm using the fluorescence JC-1 dye and a flow cytometry technique.
Indeed, a quick ∆Ψm loss was detected in 22Rv1 cells after 2 h of treatment (Figure 5D,E). In line
with this finding, we observed a release of mitochondrial proteins, namely apoptosis-inducing factor
(AIF) and cytochrome C into the cytoplasm (Figure 5F). This was associated with an induction of two
apoptotic markers, i.e., PARP- and caspase-3-cleavage (Figure 5F) and therefore may also contribute
to induction of the drug-induced apoptosis. Remarkably, CCCP–a well-established mitochondrial
oxidative phosphorylation uncoupler–exhibited comparable effects on∆Ψm and mitochondrial proteins
release like compounds 7 and 11, suggesting a similar mode of action (Figure 5D–F). Additionally, it
has been shown that conjugates 7 and 11 induce up-regulation of Bax and down-regulation of Bcl-2,
which may also contribute to the disruption of mitochondrial membrane permeability and ∆Ψm loss
(Figure 5G). Finally, it is important to note that the cleavage of caspase-9 in the cells treated with 7 and
11 was observed already after 2 h following the treatment and prior to the caspase-3 cleavage (which
was detected only 48 h following the treatment) (Figure 5H). These data strongly suggest mitochondria
as a primary target of the monoprotected glucose conjugates 7 and 11 (Figure 5I).
3. Discussion
Increased selectivity and efficacy can be achieved by linking cytotoxic anticancer drugs to
specific target/carrier molecules [9]. Successful examples of this treatment strategy are antibody-drug
conjugates, which target cancer cells due to increased expression of specific proteins [34], and folate
conjugates, which utilize a commonly high expression of the folate receptor (FR) on the surface of
different human cancer cells [35].
Warburg effect targeting is another promising strategy for the design and synthesis of new
cytotoxic anticancer drugs. Here, the conjugation of sugar residues to cytotoxic drugs shall increase
selectivity to cancerous tissues and reduce side effects in patients due to a higher sugar uptake by
the cancer cells [4,9]. To date one sugar-conjugated molecule glufosfamide is in clinical development
for the treatment of lung, ovary, pancreatic, brain and CNS cancer as well as soft tissue sarcoma [36].
In addition, different sugar-conjugated molecules are currently evaluated preclinically [4,9]. In prostate
cancer Warburg effect was observed specifically in metastatic tumors which makes glucose-derived
chemotherapeutics promising in the treatment of metastatic CRPC [37]. In our research, we found the
derivatives of natural 1,4-naphtoquinone compounds to be active in drug-resistant prostate cancer
cells. Preliminary data, however, have shown that these substances are also rather cytotoxic for
non-cancerous cells, suggesting undesired side effects in vivo. Therefore, we utilized the Warburg
effect in order to increase the selectivity of the compounds towards tumor cells. We synthesized
hybrid molecules, which contain selected natural 1,4-naphtoquinone moieties conjugated with
glucose residues via non-glycoside bond at C6 position. The non-glycoside nature of the conjugates
was chosen in order to provide the highest affinity to glucose transporters located in the cellular
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membrane. It is known that the presence of free unsubstituted glycoside hydroxyl (at C1 position)
is important for the stabilization of hydrogen bonding interactions with GLUT-1 and therefore is
required for the successful cellular uptake of the sugar-conjugated molecules [38]. In contrast, the
hydroxyl at C6 position of glucose molecule is not relevant for the hydrogen bond interactions and
therefore it’s substitution may be more tolerable [38]. In fact, the affinity of glucose with substituted
C6-OH to GLUT-1 was reported to be almost equal to its unsubstituted analogues [39]. Therefore,
instead of a conventional glycosylation reaction (results in C1-substituted glucose) we applied
a new reaction of alkylation of 2-hydroxy-1,4-naphthoquinones with 6-deoxy-6-iodo-1,2:3,5-di-O-
isopropylidene-α-D-glucofuranose (results in a C6-substituted glucose). This reaction was more
efficient in comparison with transesterification reaction of 2-methoxy-1,4-naphthoquinones, which was
recently discovered by us [16,17,40]. Thus, we synthesized a series of 6-(1,4-naphtoquinonyl)-D-glucose
conjugates containing diprotected, monoprotected, or unprotected glucose residues.
In line with our hypotheses the glucose-conjugated compounds revealed higher selectivity towards
five human prostate cancer cell lines compared with five non-cancerous lines. The successful targeting
of the Warburg effect by the newly synthesized glucose derivatives is strongly suggested by the
following findings: (a) correlation of cytotoxicity and selectivity of the synthesized conjugates with
higher expression of GLUT-1 in human prostate cancer cells; (b) inhibition of cytotoxicity of the
conjugates by addition of glucose to the media; c) ability of the compounds to inhibit a glucose uptake
by cancer cells. In general, the binding of the quinone core with the glucose moiety lead to an increased
water solubility and selectivity. However, at the same time it resulted in an absolute cytotoxicity
decrease when compared to methoxy derivatives, most probably due to the increased polarity of the
molecule. It should also be noted that normal prostate cells are known to have an active glycolysis and
also consume significant amount of glucose (reviewed in [37]). Thus, these cells may also be affected
by the Warburg effect targeting therapeutics in vivo. However, frequently patients with advanced
prostate cancer have had local treatment for their primary tumors leaving no vital tissue behind. In the
patients cytoreduction of the remaining prostate tissue maybe a pleasant side effect in order to avoid
local complications.
The four most promising compounds were selected for further examinations of activity and
the mechanism of action. Namely, conjugates 11 and 12 belonging to the structural family of
8-hydroxy-1,4-naphtoquinone-2-yl (3-hydroxyjuglone) derivatives and containing monoprotected
and free glucose, respectively, as well as conjugates 7 and 8, which belong to the structural family
of 5-hydroxy-1,4-naphtoquinone-2-yl (2-hydroxyjuglone) derivatives. These compounds exhibited
pronounced anticancer activity, executed via induction of p21- and caspase-related apoptotic tumor
cell death, and were able to suppress the colony formation of cancer cells (in vitro prototype of the
anti-metastatic activity). Note, despite of the observed up-regulation of p21 no significant cell cycle
arrest was found, which could be a cell specific phenomenon; whereas the p21 down-regulation
detected at the higher concentrations of the drugs maybe a result of protein degradation driven by
cell death associated processes. Interestingly, monoprotected conjugates 7 and 11 may have slightly
different effects on cancer cells primarily targeting the metabolism, whereas free glucose containing
conjugates 8 and 12 rather have a membranolitic activity. All four compounds effectively suppressed
pro-survival processes, associated with drug resistance of prostate cancer cells. Thus, inhibition of
cytoprotective autophagy, down-regulation of expression of anti-apoptotic protein survivin as well
as suppression of AR- and AR-V7-dependent signaling (via down-regulation/degradation of both
androgen receptors) were observed. Drug resistance remains a major challenge in prostate cancer
treatment. Up to 30% of patients with CRPC are preliminary resistant to the first line drugs and
basically all the patients over time eventually develop drug resistance to applied therapeutics [41].
Up-regulated autophagy was found in a number of prostate cancer tumors and therefore is considered
to be an important resistance mechanism to chemo- and radiotherapies in CRPC [23]. Expression
of AR-V7 has recently emerged to be an important mechanism of resistance to androgen receptor
targeting therapies such as abiraterone and enzalutamide [27,42]. Thus, novel therapeutics which are
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able to overcome drug resistance and reveal cytotoxic activity at the same time are of high value and
interest. It is important to note that no correlation of the drug-sensitivity and the cellular AR status
has been observed; e.g., 22Rv1 (AR+, AR-V7+) and DU145 (AR−, AR-V7−) cells were more sensitive
to the tested compounds in comparison with VCaP (AR+, AR-V7+) and PC-3 (AR−, AR-V7−) cells
(Figure 1D), whereas LNCaP cells (AR+, AR-V7−, hormone therapy sensitive) exhibited an average
sensitivity level. Thus, hormone therapy resistant prostate cancer cells exhibit no cross-resistance to
the investigated conjugated.
Further examinations on the mode of action were performed for conjugate 11 using global
proteome analysis. Conjugate 11 was chosen because it was the most promising out of the synthesized
compounds based on the results of cytotoxicity and selectivity profile analyses. Using consequent
bioinformatical analysis we were able to predict and further validate an activation of pro-apoptotic
MAPK, namely p38 and JNK1/2 as well as Akt, while ERK1/2, playing an important role in a number
of pro-survival processes was suppressed. This may further contribute to the ability of the substance
to overcome drug resistance. Further analysis of proteomics data suggested treatment-mediated
alteration of oxidative phosphorylation, which takes place in the inner mitochondrial membrane.
Indeed, we were able to further confirm the targeting of mitochondria of the cancer cells and showed
an elevation of the cytotoxic ROS levels as well as release of the cytotoxic mitochondrial proteins
AIF and cytochrome C to cytoplasm. Simultaneously, we observed an increased Bax/Bcl-2 ratio,
which is known to lead to mitochondrial dysfunction, followed by cytochrome C release and caspases
activation, both ultimately leading to apoptosis (reviewed in [43]). Importantly, the drop down of the
mitochondrial inner membrane potential (∆ψm), ROS up-regulation and cleavage of caspase-9 were
observed after only 2 h following the treatment. Caspase-9 is an initiator caspase, which is activated
(cleaved) in mitochondria-mediated apoptosis and later leads to the activation of effector caspase-3
(reviewed in [43]). The cleavage of caspase-9 prior to caspase-3 proves a canonical character of the
caspases activation by the synthesized compounds and confirms that the activation is not an unspecific
event resulting from cell death. Finally, mitochondrial targeting by conjugates 7 and 11 also explains
the difference in IC50s generated with MTT and trypan blue exclusion assays for these compounds.
The readout of MTT assay depends on the mitochondrial activity, and disruption/suppression of this
activity prior to the cellular membrane rupture may therefore be detected by MTT assay, but not by
trypan blue exclusion assay. Remarkably, cytotoxic activity of the compounds was also observed after
2 h treatment with the drugs in 22Rv1 cells. However, IC50 values were distinctly higher than after 48
h (IC50 = 24.2 µM, 92.39 µM, 20.45 µM, and 94.85 µM for conjugated 7, 8, 11, and 12, respectively, after
2 h or treatment). Thus, following the 2 h treatment the cytotoxic events has been already initiated but
yet not completely exerted. This is in line with the detection of delayed effector caspase-3 activation,
which occurs after longer treatment time (>2 h).
Anticancer drugs specifically targeting mitochondria attracted attention in the last 10 years
and attempts have been made in order to introduce mitochondrial targeting moieties into existing
drugs [44]. Remarkably, these drugs were reported to be more effective than their parental molecules
(e.g., fluorouracil conjugated with selective mitochondria-localized moiety F16 [45]) and some were
reported to be able to overcome drug resistance [44,46]. Recently, it has been demonstrated that
oxidative phosphorylation is up-regulated in different cancer entities, including prostate cancer
(specifically in primary tumors) [32,37]. Moreover, its correlation with hormone resistance of prostate
cancer cells has been reported (reviewed in [47]). Consequently, the interest to inhibitors of oxidative
phosphorylation, as a novel emerging target, has greatly increased [32]. During glycolysis the glucose
molecule breaks down to pyruvate, which is later transported to mitochondria and further oxidized in
Krebs cycle. Thus, inside of a living cell the quinone-conjugated glucose residue may be converted
to pyruvate which can be further specifically delivered to mitochondria. Therefore, mitochondria
targeting by the synthesized compounds could be promoted by their glucose-conjugate nature. Of note,
the non-glycoside bond in these molecules cannot be easily hydrolyzed by the cytoplasmatic enzymes,
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hence the “warhead” quinone moieties may enter mitochondria still being glucose/pyruvate-conjugated
which again contributes to their specificity.
4. Materials and Methods
4.1. Reagents and Antibodies
The investigated compounds have been synthesized as described in Supplementary information.
The purity of the individual compound was verified by TLC, 1H- and 13C-NMR spectroscopy (Table S2).
For details of synthesis, purification and structure elucidation see the Supplementary Information.
Other reagents are listed in the Supplementary Information. Antibodies used are listed in Table S3.
4.2. Cell Lines and Culture Conditions
For general experiments human prostate cancer cell lines PC-3 and DU145 (docetaxel-resistant,
androgen-independent, AR-FL(−), AR-V7(−)), 22Rv1 and VCaP (docetaxel-sensitive,
androgen-independent, AR-FL(+), AR-V7(+), and LNCaP (docetaxel sensitive, androgen-dependent,
AR-FL(+), AR-V7(−) were used [18–20]. PC-3, 22Rv1, LNCaP cells as well as the human prostate
non-cancer cells PNT2 and RWPE-1 were purchased from ATCC (Manassas, VA, USA). VCaP were
purchased from ECACC (Salisbury, UK). The human fibroblast cell line MRC-9, the human embryonic
kidney cell line HEK 293T, as well as the human umbilical vascular endothelial cell line HUVEC were
kindly donated by Prof. Dr. Dr. med. Sonja Loges (University Medical Center Hamburg-Eppendorf,
Hamburg, Germany). Cells were cultured according to the manufacturers’ instructions and were
recently authenticated by a commercial service (Multiplexion, Heidelberg, Germany). Culture
conditions are described in the Supplementary Information.
4.3. In Vitro MTT-Based Drug Sensitivity Assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cytotoxicity assay was used
for the evaluation of cytotoxicity of the compounds or their combinations. Experiments were performed
as previously described [48]. In brief, 6000 cells/well were seeded in 96-well plate, incubated overnight,
and treated with the drugs in 100 µL/well of 10% FBS/RPMI media containing 2 g/L of D-(+)-glucose
for 48 h, unless otherwise stated. For 2 h treatment the cells were treated with the drugs for 2 h in the
culture media, then the media was exchanged to fresh drug-free media (100 µL/well) containing MTT
reagent and the further steps were performed as previously described [48].
4.4. In Vitro Trypan Blue-Based Viability Assay
The in vitro effect of the drugs on cell viability and proliferation was evaluated using trypan
blue exclusion assay as described before with minor modifications [49]. In brief, cells (0.2 × 106
cells/well) were seeded in 12-well plates, incubated overnight, the media was replaced with fresh
media (1 mL/well) and treated with the drugs for 48 h. Cells were harvested by trypsination and the
viability was measured using trypan blue staining and Beckman Coulter Vi-CELL (Beckman Coulter,
Krefeld, Germany).
4.5. ELISA
To determine the expression of GLUT-1 in the ten non-treated cell lines the ELISA kit for Glucose
transporter-1 (#SEB184Hu, Cloud-Clone Corp., Houston, TX, USA) was used. Human prostate cancer
cells (PC-3, DU145, 22Rv1, VCaP, and LNCaP) and human non-cancer cells (MRC-9, HUVEC, HEK 293,
PNT2, and RWPE-1) were seeded in the ø 6 cm TC dishes (1 × 106 cells/well in 5 mL/dish of culture
media), incubated overnight and then harvested with scratching, resuspended in Western blotting
lysis buffer and proceeded according to the manufacture’s protocols. For this assay 30 µg/well of total
protein in 100 µL/well were loaded.
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4.6. Glucose Uptake Assay
The effects of the compounds on glucose uptake were determined by Glucose Uptake Cell-Based
Assay Kit (Cayman chemicals, Ann Arbor, MI, USA). PC-3 or 22Rv1 cells (100,000 cells/well) were
seeded into 12-well plates, incubated overnight and treated with the investigated drugs in 500 µL/well
of glucose-free 0.1% FBS/RPMI media for 24 h. Then, the 50 µL/well of 2-NBDG solution (400 µg/mL)
in glucose-free 0.1% FBS/RPMI media were added to each well (final concentration of 2-NBDG in
wells was 40 µg/mL). After 2 h of incubation the cells were harvested by trypsination, washed with
PBS and resuspended in 100 µL/sample of PI/PBS solution (1 µg/mL). Following 10 min incubation,
300 µL/sample of PBS were added and the glucose uptake in viable (PI-negative) cells was evaluated
using flow cytometry technique and quantified using BD Bioscience Cell Quest Pro v.5.2.1. software.
4.7. Colony Formation Assay
Colony formation assays were performed as described before [49]. In brief, cells were treated with
the drugs for 48 h and then 100 alive cells were plated into each well of 6-well plates and incubated for
10 days. Surviving colonies were fixed, stained with Giemsa solution and counted.
4.8. Cell Cycle and DNA Fragmentation Analysis
The effect on cell cycle progression was analyzed by flow cytometry technique using PI staining
as reported before [48]. In brief, cells were pre-incubated overnight in 6-well plates (0.2 × 106 cells/well
in 2 mL/well), treated with the drugs for 48 h. Then cells were harvested, fixed, stained with PI, and
analyzed using FACS Calibur (BD Bioscience, San Jose, CA, USA) and BD Bioscience Cell Quest Pro
v.5.2.1. software (BD Bioscience).
4.9. Detection of Apoptotic Cells by Annexin-V-FITC/PI Double Staining
Induction of apoptosis was analyzed by flow cytometry technique using annexin-V-FITC and
propidium iodide (PI) double staining. The experiment was performed as previously described [16].
In brief, cells were seeded and treated as described for the cell cycle analysis, cells were harvested by
trypsination, stained, and analyzed using a FACS Calibur machine and BD Cell Quest Pro software.
4.10. Protein Preparation and Western Blotting
Preparation of protein extracts for western blotting was performed as described previously [20,50].
In brief, for western blotting, 1 × 106 cells/well were seeded in Petri dishes (ø 6 cm TC Dish (Sarstedt,
Numbrecht, Germany) in 5 mL/dish), incubated overnight and treated with drugs in 5 mL/dish for an
indicated time. Cells were harvested using a cell scraper, pelleted, and resuspended in the lysis buffer
containing protease and phosphatase inhibitors. Further sample preparation and western blotting
were performed as previously described with slight modifications [20,50]. Relative optical density
of the detected bands was quantified with Quantity One 4.6 software (Bio-Rad, Hercules, CA, USA).
The primary and secondary antibodies used are listed in the Supplementary Information.
4.11. Proteomic Analysis of the Differentially Expressed Proteins
22Rv1 cells were seeded in T75 culture bottles (4 × 106 cells/bottle in 20 mL/bottle), treated for 48 h
with the 5 µM of compound 11 or vehicle (DMSO), harvested by scratching, washed twice with ice-cold
PBS and flash-frozen. Cells were lysed and sonicated. The protein extracts were then heat-denaturated,
reduced, alkylated and digested by trypsin. Peptides were chromatographically separated using full
recovery autosampler vials and a nano-UPLC system (Acquity, Waters Corporation, Milford, MS,
USA), coupled via electrospray ionization (ESI) to a tandem mass spectrometer equipped with a
quadrupole and an orbitrap (QExactive, Thermo Fisher Scientific, Bremen, Germany), using MS/MS
mode in data dependent acquisition (DDA) and data independent acquisition (DIA). The peptides,
analyzed with DDA-LC-MS/MS, were identified with the search engine Sequest, integrated in the
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Proteome Discoverer software version 2.0 (Thermo Fischer Scientific) using the human Uniprot protein
database (EMBL; Hinxton Cambridge, UK, release December 2018). Proteins were considered to be
significantly regulated if 1.5 ≤ fold change ≤ 1/1.5 and p ≤ 0.05 (Student’s t-test). For the details of
sample preparation and proceeding, data acquisition and analysis see the Supplementary information.
4.12. Bioinformatics Analysis of Differentially Expressed Proteins
Network analyses and gene ontology classification were performed using the Ingenuity Pathways
Analysis (IPA) (QIAGEN Bioinformatics, Venlo, The Netherlands, https://www.qiagenbioinformatics.
com/products/ingenuity-pathway-analysis/) algorithms. The list of significantly regulated proteins
(1.5 ≤ fold change ≤ 1/1.5; p ≤ 0.05) discovered by global proteome analysis were inserted into the
IPA software to explore the gene ontology, protein interaction networks as well as relevant biological
molecules and processes affected by the drug. z-Score algorithm analysis was used to identify
biological functions which are expected to be activated (z-score > 0) or suppressed (z-score < 0) in
the cells upon treatment. The p-values were calculated with the Fischer’s exact test by IPA software.
The shortest hypothetical pathway network was constructed, showing the most relevant direct and
indirect connections of proteins found to be regulated by the compound.
4.13. Evaluation of Intracellular ROS
Intracellular ROS levels were estimated using the ROS-sensitive CM-H2DCFDA reagent (Cat. No.
C6827, Molecular probes, Invitrogen, Eugene, OR, USA) as described before [51]. In brief, 22Rv1 cells
were seeded in 12-well plates (0.2 × 106 cells/well in 1 mL/well of media) and incubated overnight.
The media was changed into freshly made pre-warmed 4 µM CM-H2DCFDA/PBS (0.5 mL/well) and
incubated for 30 min (37 ◦C, 5% CO2, in the dark). Then, the CM-H2DCFDA solution was exchanged
with 1 mL/well of pre-warmed PBS containing the drugs or H2O2 (positive control) at the indicated
concentrations. After 2 h of incubation the cells were trypsinized and immediately analyzed by flow
cytometry technique according to the manufacture’s protocols.
4.14. Mitochondrial Membrane Potential (∆ψ) Assay
The loss of mitochondrial membrane potential (∆ψ) was measured by flow cytometry technique
using staining with ∆ψ-sensitive dye JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylimidacarbocyanine
iodide). Cells were seeded in 12-well plates (100 × 103 cells/well in 1 mL/well) and incubated overnight.
Then, the media was changed to PBS (1 mL/well) containing the investigational drugs. After 2 h of
incubation (37 ◦C, 5% CO2, in the dark) the cells were trypsinized, pelleted, resuspended in 100 µL
of 2 µM JC-1/PBS, incubated for 1 h (37 ◦C, 5% CO2, in the dark) and ∆ψ loss was measured by flow
cytometry technique.
4.15. Cell Fractionation
22Rv1 cells were seeded in T75 culture bottles (4 × 106 cells/bottle in 20 mL/bottle), treated for 48
h and harvested by scratching. The further separation of cytosolic, mitochondrial and nuclear fractions
was performed using the Cell Fractionation Kit ab109719 (abcam, Cambridge, MA) as previously
described [51]. Mitochondrial and cytosolic fractions were concentrated using Amicon® Ultra-2
Centrifugal Filter device (Cat. No. UFC203024, Merck, Darmstadt, Germany). Nuclear fractions were
additionally homogenized using QIAshedder kit (QIAGEN, Hilden, Germany).
4.16. Statistical Analysis
Statistical analyses were performed using GraphPad Prism software v. 5.01 (GraphPad Prism
software Inc., La Jolla, CA, USA). Data are presented as mean ± SEM (standard error of the mean).
All the experiments were performed in triplicates and repeated at least three times. The unpaired
Student’s t-test was used for comparison of two groups. The one-way analysis of variance (ANOVA),
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followed by a post-hoc Dunnett’s test was used for multiple groups comparisons. Differences were
considered to be statistically significant if p < 0.05.
5. Conclusions
In conclusion, we found natural 1,4-naphtoquinone derivatives with promising anti-cancer
activity in human drug-resistant prostate cancer cells and synthesized new glucose derivatives
(6-O-(1,4-naphtaquinone-2-yl)-D-glucose conjugates) with improved selectivity. The compounds
exhibited selective cytotoxicity in human prostate cancer cells due to a higher uptake rate, which
most likely results from the Warburg effect. The glucose conjugates were able to overcome cancer cell
drug resistance and suppress pro-survival mechanisms. Cytotoxic activity is executed via primary
intracellular targeting of cancer cell mitochondria leading to cytotoxic ROS production as well as to
AIF and cytochrome C release to cytoplasm, which results in caspase-9 and -3 activation and ultimately
leads to apoptotic death of cancer cells (Figure 5I). Our simple and effective way of total synthesis of
these compounds enables us to produce amounts necessary for further in vivo testing and clinical trials.
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Abbreviations
2-NBDG 2-deoxy-2-((7-nitro-2,1,3-benzoxadiazol-4-yl)amino)-D-glucose
∆Ψm mitochondrial membrane potential (MMP)
AIF apoptosis inducing factor
Apig apigenin
Aniso anisomycin
AR androgen receptor
AR-V7 androgen receptor splice variant 7
CCCP carbonyl cyanide 3-chlorophenylhydrazone
Ccl-B cytochalasin B
CRPC castration-resistant prostate cancer
Glc glucose
GLUT-1 glucose transporter-1
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NaC N-acetyl-L-cysteine
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Plt phloretin
ROS reactive oxygen species
RT room temperature
SI selectivity index
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